Literature DB >> 6678306

Growth, morphology, and serial transplantation of anaplastic human gliomas in athymic mice.

S C Schold, D E Bullard, S H Bigner, T R Jones, D D Bigner.   

Abstract

Sixteen of 17 anaplastic human gliomas (AHGs) transplanted into athymic mice produced progressively growing subcutaneous nodules at the site of implantation. Thirty-four of 68 animals (50%) receiving transplanted tissue developed 500 m3 tumors in 24 to 364 days. Fourteen AHG were passed to a second animal generation, and 11 showed continued growth. Eight of these were serially passed, with one reaching a sixth animal generation, four reaching a fifth, and a three third. Once growth occurred in a second animal generation, no AHGs were lost in subsequent passages because of failure to grow. Of 234 animals receiving tumors beyond the first animal generation, 189 (80.8%) developed tumors. Average doubling times of the exponentially growing tumors in serial passage ranged from 3.0 to 19.1 days. This growth rate tended to increase and stabilize in early animal passages. The tumors growing in animals contained cell types which were present in the original human tumors, including fibrillary and protoplasmic astrocytes, small anaplastic cells, gemistocytes, anaplastic spindle cells, and multinucleate giant cells. Glial fibrillary acidic protein (GFAP) was detected in 15 of 17 biopsy specimens and in 12 of 14 AHGs in animals. These data illustrate the value of the athymic mouse system for the investigation of human brain tumors by demonstrating a high rate of successful transplantation, quantitative growth data on serially passed tumors, and morphological and immunochemical resemblance of the tumors in mice to the original human tumors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6678306     DOI: 10.1007/bf00153635

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  21 in total

1.  Heterotransplantation of human glioblastoma multiforme and meningioma to nude mice.

Authors:  M W Rana; H Pinkerton; H Thornton; D Nagy
Journal:  Proc Soc Exp Biol Med       Date:  1977-05

2.  Human brain tumor transplantation into nude mice.

Authors:  W R Shapiro; G A Basler; N L Chernik; J B Posner
Journal:  J Natl Cancer Inst       Date:  1979-03       Impact factor: 13.506

3.  Contribution of immunohistochemistry to diagnostic problems of human cerebral tumors.

Authors:  L F Eng; L J Rubinstein
Journal:  J Histochem Cytochem       Date:  1978-07       Impact factor: 2.479

4.  Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas.

Authors:  J R Shapiro; W K Yung; W R Shapiro
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

5.  Chemotherapy of human tumor xenografts in genetically athymic mice.

Authors:  A A Ovejera; D P Houchens; A D Barker
Journal:  Ann Clin Lab Sci       Date:  1978 Jan-Feb       Impact factor: 1.256

6.  Twenty-three new human tumor lines established in nude mice.

Authors:  J Fogh; T Orfeo; J Tiso; F E Sharkey; J M Fogh; W P Daniels
Journal:  Exp Cell Biol       Date:  1980

7.  Cell kinetic study of human cancers transplanted to nude mice.

Authors:  S Ikeuchi; Y Shimosato; T Kameya; S Watanabe; T Kakegawa; O Abe
Journal:  Exp Cell Biol       Date:  1980

8.  Biology of gliomas: potential clinical implications of glioma cellular heterogeneity.

Authors:  D D Bigner
Journal:  Neurosurgery       Date:  1981-09       Impact factor: 4.654

9.  Heterotransplantation of human cancers into nude mice: a model system for human cancer chemotherapy.

Authors:  B C Giovanella; J S Stehlin; L J Williams; S S Lee; R C Shepard
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

10.  Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X-irradiated nude mice.

Authors:  Y Ohsugi; M E Gershwin; R B Owens; W A Nelson-Rees
Journal:  J Natl Cancer Inst       Date:  1980-10       Impact factor: 13.506

View more
  5 in total

1.  In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line.

Authors:  P Fredman; C J Wikstrand; J E Månsson; G Reifenberger; S H Bigner; A Rasheed; L Svennerholm; D D Bigner
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

2.  Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor.

Authors:  Ganesan Vaidyanathan; Oscar R Pozzi; Jaeyeon Choi; Xiao-Guang Zhao; Shawn Murphy; Michael R Zalutsky
Journal:  Cancer Biother Radiopharm       Date:  2020-02-28       Impact factor: 3.099

Review 3.  Human tumor xenografts as model for drug testing.

Authors:  J Mattern; M Bak; E W Hahn; M Volm
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

4.  Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses.

Authors:  C A Kruse; D H Mitchell; B K Kleinschmidt-DeMasters; W A Franklin; H G Morse; E B Spector; K O Lillehei
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

5.  Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell lines.

Authors:  C A Kruse; M Varella-Garcia; B K Kleinschmidt-Demasters; G C Owens; E B Spector; H Fakhrai; E Savelieva; B C Liang
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-06       Impact factor: 2.723

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.